PXS:LSE Provexis plc

GBX 0.68 0.00 0
Icon

Provexis plc (PXS:LSE) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | LSE
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

GBX 0.68

0.00 (0.00)%

GBX 0.01B

1.49M

N/A

N/A

Icon

PXS:LSE

Provexis plc (GBX)
COMMON STOCK | LSE
GBX 0.68
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

GBX 0.01B

N/A

GBX 0.68

Provexis plc (PXS:LSE) Stock Forecast

N/A

Based on the Provexis plc stock forecast from 0 analysts, the average analyst target price for Provexis plc is not available over the next 12 months. Provexis plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Provexis plc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Provexis plc’s stock price was GBX 0.68. Provexis plc’s stock price has changed by +3.85% over the past week, -1.82% over the past month and -22.86% over the last year.

No recent analyst target price found for Provexis plc
No recent average analyst rating found for Provexis plc

Company Overview Provexis plc

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardi...Read More

https://www.provexis.com

I Ford, Reading, United Kingdom, RG1 1AZ

2

March

GBX

UK

Adjusted Closing Price for Provexis plc (PXS:LSE)

Loading...

Unadjusted Closing Price for Provexis plc (PXS:LSE)

Loading...

Share Trading Volume for Provexis plc Shares

Loading...

Compare Performance of Provexis plc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for PXS:LSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Provexis plc (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HLN:LSE
Haleon PLC 0.00 (0.00%) GBX29.99B 24.75 16.66

ETFs Containing PXS

Symbol Name PXS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Provexis plc (PXS:LSE) Stock

Stock Target Advisor's fundamental analysis for Provexis plc's stock is Slightly Bearish.

Unfortunately we do not have enough data on PXS:LSE's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on PXS:LSE's stock to indicate what its average analyst target is.

PXS:LSE stock's Price/Earning ratio is 0.46. Our analysis grades PXS:LSE stock's Price / Earning ratio at A+. This means that PXS:LSE stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the LSE exchange. Based on this PXS:LSE may be undervalued for its sector.

The last closing price of PXS:LSE's stock was GBX 0.68.

The most recent market capitalization for PXS:LSE is GBX 0.01B.

Unfortunately we do not have enough analyst data on PXS:LSE's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Provexis plc's stock.

As per our most recent records Provexis plc has 2 Employees.

Provexis plc's registered address is I Ford, Reading, United Kingdom, RG1 1AZ. You can get more information about it from Provexis plc's website at https://www.provexis.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...